CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Revenues	$ 2,048.4	$ 1,663.5	$ 5,693.9	$ 4,783.0
Expenses:
Research and development	663.4	557.0	2,353.5	1,584.8
Selling, general, and administrative	419.9	369.2	1,248.0	1,064.9
Total expenses	1,309.9	1,036.6	4,159.8	2,966.7
Income from operations	738.5	626.9	1,534.1	1,816.3
Other income (expense):
Other income (expense), net	37.8	16.4	28.7	81.8
Interest expense	(7.8)	(7.4)	(23.5)	(20.8)
Total other income (expense)	30.0	9.0	5.2	61.0
Income before income taxes	768.5	635.9	1,539.3	1,877.3
Income tax expense	(98.9)	(41.2)	(215.5)	(253.3)
Net income	$ 669.6	$ 594.7	$ 1,323.8	$ 1,624.0
Net income per share - basic (in dollars per share)	$ 6.12	$ 5.50	$ 12.12	$ 15.06
Net income per share - diluted (in dollars per share)	$ 5.86	$ 5.17	$ 11.54	$ 14.14
Weighted average shares outstanding - basic (in shares)	109.4	108.0	109.2	107.8
Weighted average shares - diluted (in shares)	114.2	115.1	114.7	114.8
Statements of Comprehensive Income
Net income	$ 669.6	$ 594.7	$ 1,323.8	$ 1,624.0
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on debt securities	1.0	0.7	31.5	(6.9)
Unrealized (loss) gain on cash flow hedges	(0.3)		(2.7)
Unrealized (loss) gain on cash flow hedges		0.3		2.4
Comprehensive income	670.3	595.7	1,352.6	1,619.5
Product
Revenues:
Revenues	1,238.3	1,025.5	3,548.0	3,009.8
Expenses:
Cost of goods sold	115.9	30.8	253.8	136.1
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	110.7	79.6	304.5	180.9
Sanofi | Product and service, other
Revenues:
Revenues	404.2	256.3	999.7	683.5
Bayer | Product and service, other
Revenues:
Revenues	302.8	264.4	868.0	775.2
Other | Product and service, other
Revenues:
Revenues	$ 103.1	$ 117.3	$ 278.2	$ 314.5